TABLE 1.
Baseline Demographics and Clinical Characteristics Before or at Start of 177Lu-PSMA
| Characteristic | Data |
|---|---|
| Patients | 133 |
| Age (y) | 73 (49–90) |
| ECOG PS | |
| 1 | 82 (62) |
| 2 | 51 (38) |
| PSA* (ng/mL) (n = 130) | 286 (1–12,229) |
| ALP* (U/L) (n = 112) | 146 (23–973) |
| Extent of metastatic disease† | |
| Bone metastases with lymph node metastases | 63 (47) |
| Bone metastases without lymph node metastases | 33 (25) |
| Visceral metastases | 36 (27) |
| Prior therapies for mCRPC | |
| ≥4 life-prolonging therapies‡ | 75 (56) |
| 223Ra | 133 (100) |
| Injections | |
| 1–4 | 35 (26) |
| 5–6 | 98 (74) |
| Abiraterone | 95 (71) |
| Enzalutamide | 92 (69) |
| Abiraterone and enzalutamide | 71 (53) |
| Chemotherapy lines§ | |
| 0 | 31 (23) |
| 1 | 67 (50) |
| ≥2 | 35 (26) |
| Docetaxel | 99 (74) |
| Cycles‖ | |
| 1–4 | 27 (24) |
| ≥5 | 59 (53) |
| Missing/unknown | 26 (23) |
| Cabazitaxel | 30 (23) |
| Cycles¶ | |
| 1–4 | 7 (21) |
| ≥5 | 14 (42) |
| Missing/unknown | 12 (36) |
In case of multiple measures, value nearest to 177Lu-PSMA start was chosen.
Prebaseline period, patient may have multiple metastatic diseases.
Docetaxel, cabazitaxel, abiraterone, enzalutamide, 223Ra.
Chemotherapies with same start date ± 15 d were counted as 1 line.
n = 112; percentages were based on number of docetaxel therapies (i.e., patients who received 2 lines of docetaxel were counted twice).
n = 33; percentages were based on number of cabazitaxel therapies (i.e., patients who received 2 lines of cabazitaxel were counted twice).
ECOG PS = Eastern Cooperative Oncology Group performance status.
Qualitative data are number and percentage; continuous data are median and range.